| MRSN |
Mersana Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
5.5% |
$2,122,973 |
-$41,906,118 |
273,579 |
-95% |
Schonfeld Strategic Advisors LLC |
30 Sep 2025 |
| TERN |
Terns Pharmaceuticals, Inc. |
Common Stock, par value $0.0001 per share |
4.9% |
$9,901,969 |
-$2,137,399 |
4,305,204 |
-18% |
Schonfeld Strategic Advisors LLC |
31 Mar 2025 |
| SKYE |
Skye Bioscience, Inc. |
Common Stock, par value $0.001 per share |
3.6% |
$3,861,149 |
-$1,736,083 |
1,115,939 |
-31% |
Schonfeld Strategic Advisors LLC |
30 Jun 2025 |
| APLT |
Applied Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
3.3% |
$1,496,351 |
-$1,309,934 |
4,676,097 |
-47% |
Schonfeld Strategic Advisors LLC |
31 Mar 2025 |
| RVPH |
Reviva Pharmaceuticals Holdings, Inc. |
Common Stock, par value $0.0001 per share |
2.8% |
$762,651 |
|
1,314,915 |
|
Schonfeld Strategic Advisors LLC |
31 Dec 2024 |
| FATE |
Fate Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
0.82% |
$1,050,024 |
-$7,679,831 |
937,521 |
-88% |
Schonfeld Strategic Advisors LLC |
30 Jun 2025 |